Cargando…
Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor
BACKGROUND: Prompt evaluation and treatment of acute coronary syndrome has demonstrated to reduce mortality. Although several biomarkers have been studied for risk stratification and prognostic purposes, none is recommended to guide treatment based on its prognostic value. Copeptin and hepatocyte gr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050999/ https://www.ncbi.nlm.nih.gov/pubmed/35482134 http://dx.doi.org/10.1186/s43044-022-00275-9 |
_version_ | 1784696465413636096 |
---|---|
author | Pintado, María-Consuelo Maceda, Lara Trascasa, María Arribas, Ignacio De Pablo, Raúl |
author_facet | Pintado, María-Consuelo Maceda, Lara Trascasa, María Arribas, Ignacio De Pablo, Raúl |
author_sort | Pintado, María-Consuelo |
collection | PubMed |
description | BACKGROUND: Prompt evaluation and treatment of acute coronary syndrome has demonstrated to reduce mortality. Although several biomarkers have been studied for risk stratification and prognostic purposes, none is recommended to guide treatment based on its prognostic value. Copeptin and hepatocyte growth factor have been associated with poor outcome in patients with acute myocardial infarction. The aim of this study is to evaluate the early prognostic value of measurements of copeptin and hepatocyte growth factor for hospital mortality risk and 1-year-follow-up mortality, in patients with acute myocardial infarction. In our retrospective observational study, we measured hepatocyte growth factor and copeptin in blood samples collected at hospital arrival in patients with acute myocardial infarction; and follow-up them until 1-year. RESULTS: 84 patients with were included in the study, mainly male (65%) with a median age of 70.3 ± 13.56 years. Hospital mortality was 11.9%. Plasma levels of copeptin at hospital arrival were statistically significant higher in patients who died during hospital admission (145.60 pmol/L [52.21–588.50] vs. 24.79 pmol/L [10.90–84.82], p 0.01). However, we found no statistically significant association between plasma levels of hepatocyte growth factor and hospital mortality (381.05 pg/ml [189.95–736.65] vs. 355.24 pg/ml [175.55–521.76], p 0.73). 1-year follow-up mortality was 21.4%. Plasma levels of copeptin at hospital arrival were higher in those patients who died in the following year (112.28 pmol/L [25.10–418.27] vs. 23.82 pmol/L [10.96–77.30], p 0.02). In the case of HGF, we also find no association between hepatocyte growth factor plasma levels and 1 -year follow-up mortality (350.00 pg/ml [175.05–555.08] vs. 345.53 pg/ml [183.68–561.15], p 0.68). CONCLUSIONS: In patients with acute myocardial infarction measurement of copeptin at hospital arrival could be a useful tool to assess the prognosis of these patients, since their elevation is associated with a higher hospital mortality and higher 1-year follow-up mortality. We have not found this association in the case of hepatocyte growth factor measurement. |
format | Online Article Text |
id | pubmed-9050999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-90509992022-05-13 Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor Pintado, María-Consuelo Maceda, Lara Trascasa, María Arribas, Ignacio De Pablo, Raúl Egypt Heart J Research BACKGROUND: Prompt evaluation and treatment of acute coronary syndrome has demonstrated to reduce mortality. Although several biomarkers have been studied for risk stratification and prognostic purposes, none is recommended to guide treatment based on its prognostic value. Copeptin and hepatocyte growth factor have been associated with poor outcome in patients with acute myocardial infarction. The aim of this study is to evaluate the early prognostic value of measurements of copeptin and hepatocyte growth factor for hospital mortality risk and 1-year-follow-up mortality, in patients with acute myocardial infarction. In our retrospective observational study, we measured hepatocyte growth factor and copeptin in blood samples collected at hospital arrival in patients with acute myocardial infarction; and follow-up them until 1-year. RESULTS: 84 patients with were included in the study, mainly male (65%) with a median age of 70.3 ± 13.56 years. Hospital mortality was 11.9%. Plasma levels of copeptin at hospital arrival were statistically significant higher in patients who died during hospital admission (145.60 pmol/L [52.21–588.50] vs. 24.79 pmol/L [10.90–84.82], p 0.01). However, we found no statistically significant association between plasma levels of hepatocyte growth factor and hospital mortality (381.05 pg/ml [189.95–736.65] vs. 355.24 pg/ml [175.55–521.76], p 0.73). 1-year follow-up mortality was 21.4%. Plasma levels of copeptin at hospital arrival were higher in those patients who died in the following year (112.28 pmol/L [25.10–418.27] vs. 23.82 pmol/L [10.96–77.30], p 0.02). In the case of HGF, we also find no association between hepatocyte growth factor plasma levels and 1 -year follow-up mortality (350.00 pg/ml [175.05–555.08] vs. 345.53 pg/ml [183.68–561.15], p 0.68). CONCLUSIONS: In patients with acute myocardial infarction measurement of copeptin at hospital arrival could be a useful tool to assess the prognosis of these patients, since their elevation is associated with a higher hospital mortality and higher 1-year follow-up mortality. We have not found this association in the case of hepatocyte growth factor measurement. Springer Berlin Heidelberg 2022-04-28 /pmc/articles/PMC9050999/ /pubmed/35482134 http://dx.doi.org/10.1186/s43044-022-00275-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Pintado, María-Consuelo Maceda, Lara Trascasa, María Arribas, Ignacio De Pablo, Raúl Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
title | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
title_full | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
title_fullStr | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
title_full_unstemmed | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
title_short | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
title_sort | prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050999/ https://www.ncbi.nlm.nih.gov/pubmed/35482134 http://dx.doi.org/10.1186/s43044-022-00275-9 |
work_keys_str_mv | AT pintadomariaconsuelo prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor AT macedalara prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor AT trascasamaria prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor AT arribasignacio prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor AT depabloraul prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor |